The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM–PRODIGE 63 GERCOR D17-01 study).
 
Cindy Neuzillet
Consulting or Advisory Role - SERVIER
Research Funding - Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; OSE Immunotherapeutics
 
Vincent Hautefeuille
Honoraria - Advanced Accelerator Applications; Amgen; Ipsen; Novartis; Sanofi; SERVIER; Tillotts Pharma
Research Funding - Ipsen
Travel, Accommodations, Expenses - Amgen; Ipsen; Novartis; Pfizer; Sanofi
 
Aurélien Lambert
Consulting or Advisory Role - Bayer; Janssen; Merck KGaA; Servier/Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Pfizer
 
Marie-Line Garcia-Larnicol
No Relationships to Disclose
 
Dewi Vernerey
Consulting or Advisory Role - HalioDx; Janssen-Cilag; OSE Immunotherapeutics; Pfizer
Travel, Accommodations, Expenses - MSD